1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6ACC895B1A928CC230025877400285D3F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/insights/new-report-provides-blueprint-using-disease-awareness-connect-with-patients?opendocument
18
19opendocument
203.89.204.127
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25Main






New Report Provides Blueprint on Using Disease Awareness to Connect with Patients

CHAPEL HILL, N.C., Mar. 09, 2021/PRNewswire/ -- Disease state awareness campaigns set the table for future marketing efforts at product launch and post-launch.

One of the few ways to inform patients and physicians before a product is approved, disease awareness campaigns have long been used by the pharmaceutical industry to disseminate unbranded information about the characteristics of a particular disease, and how it affects patients.

While some organizations have demonstrated strong acumen in their disease awareness programs, many drug manufacturers struggle to effectively connect their campaigns to their targeted audiences, stumble on message timing, and fail to allocate sufficient resources.

To help pharma leaders better understand how to effectively utilize disease awareness programs to support pipeline portfolio products, Best Practices, LLC has published a new research study that delivers reliable industry metrics on current disease state awareness program structure, spend, and activities.

In short, "Disease Awareness Program Excellence: Structure, Activities & Resources Needed for Effective Pipeline Support" identifies what disease awareness activities and investment levels are most effective for supporting pipeline products during both development and post-marketing periods.

Key topics covered in this 63-page report include:

  • Disease awareness program structure
  • Timing of disease awareness activities
  • Budget and spending for disease awareness programs
  • Involvement of Advocacy Groups and Legal in disease awareness
  • Use of social media for disease awareness

Pharmaceutical leaders will be able to use the research results to see how their disease awareness programs stack up against industry averages and trends.

Best Practices, LLC engaged 30 leaders from 28 top life sciences organizations in this benchmarking research. Four executives participated in deep-dive operational interviews. Secondary research is occasionally provided for context.

To learn more about this report, download a complimentary report excerpt at https://www.best-in-class.com/rw89.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.